ABC Safe Drug Act

The ABC Safe Drug Act, S.1407, introduced by Senator Cotton, mandates a phased restriction on federal health care programs purchasing drugs with active pharmaceutical ingredients (APIs) from China. By January 1, 2028, 60% or more of APIs must originate from non-Chinese, FDA-compliant countries, escalating to 100% by January 1, 2030. This bill also introduces temporary 100% expensing for qualified pharmaceutical and medical device manufacturing property placed in service between December 31, 2024, and January 1, 2031. This legislative action forces a rapid reshoring and diversification of the pharmaceutical supply chain, directly impacting drug procurement for federal programs including Medicare, Medicaid, VA, and DoD. The money trail for this bill is two-fold. First, the federal government's multi-billion dollar drug procurement budget will shift away from drugs containing Chinese APIs. This redirects significant revenue streams to pharmaceutical companies with robust non-Chinese supply chains. Second, the 100% expensing provision for manufacturing property acts as a direct subsidy for capital investment in U.S. pharmaceutical and medical device manufacturing. This tax incentive lowers the cost of new plant and equipment, encouraging companies to build or expand domestic production facilities. Companies like Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Eli Lilly ($LLY), Amgen ($AMGN), and Gilead Sciences ($GILD), which already have substantial U.S. manufacturing footprints or are actively investing in them, are positioned to capture this redirected federal spending and leverage the tax benefits. Historically, similar 'Buy American' provisions have led to significant shifts in procurement and manufacturing. For example, the American Recovery and Reinvestment Act of 2009 included 'Buy American' provisions for infrastructure projects. While not directly comparable to pharmaceuticals, these provisions led to increased domestic sourcing and investment. More recently, the CHIPS and Science Act of 2022, which provided incentives for domestic semiconductor manufacturing, saw companies like Intel ($INTC) announce multi-billion dollar investments in U.S. facilities, and its stock gained 8% in the week following the bill's passage. This bill's tax expensing provision is a direct financial incentive for similar domestic investment in the pharmaceutical sector. Specific winners include large pharmaceutical companies with existing U.S. or allied country manufacturing capabilities such as Pfizer ($PFE), Johnson & Johnson ($JNJ), Merck ($MRK), Eli Lilly ($LLY), Amgen ($AMGN), and Gilead Sciences ($GILD). Generic drug manufacturers with significant U.S. or European API production, like Viatris ($VTRS) and Teva Pharmaceutical Industries ($TEVA), also stand to gain. Pharmaceutical distributors and pharmacies, such as CVS Health ($CVS), Walgreens Boots Alliance, Cardinal Health ($CAH), McKesson ($MCK), and AmerisourceBergen, will need to adjust their procurement to comply with the new rules, favoring suppliers that meet the origin requirements. Losers are pharmaceutical companies heavily reliant on Chinese API suppliers, which will face significant costs to reconfigure their supply chains or risk losing federal contracts. The bill's sponsor, Senator Cotton, is a senior member, indicating moderate legislative momentum, especially given bipartisan concerns about supply chain security. The bill has been referred to the Committee on Finance. The next step is committee consideration, which includes hearings and potential mark-up. If it passes committee, it moves to the full Senate for a vote. The key dates for compliance are January 1, 2028 (60% non-Chinese API) and January 1, 2030 (100% non-Chinese API), with the tax expensing provision active from December 31, 2024, to January 1, 2031. The waiver authority for the API restrictions expires on January 1, 2031, indicating a firm deadline for compliance.